Ipsen: ASCO 2022: New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer

COSMIC-021 Phase Ib study is evaluating Cabometyx (cabozantinib) in combination with atezolizumab in advanced solid tumors, including non-small cell lung cancer New analyses from pivotal Phase

Related Keywords

Japan ,Serbia ,Saclay ,France General ,France ,Kazakhstan ,Australia ,Taiwan ,United States ,Shanghai ,China ,United Kingdom ,Hong Kong ,Paris ,Brazil ,Russia ,Ukraine ,Mexico ,Iceland ,New Zealand ,Santiago ,Regióetropolitana ,Chile ,Egypt ,Ecuador ,World Health Organization ,Al Qahirah ,Cambridge ,Cambridgeshire ,Panama ,South Korea ,Switzerland ,Macau ,Norway ,Malaysia ,Lebanon ,Colombia ,Canada ,Guatemala ,Jordan ,Thailand ,Israel ,Singapore ,Dominican Republic ,Saudi Arabia ,Peru ,Turkey ,Great Britain ,Russian Federation ,American ,Mon Jun ,Howard Mayer ,Ipsen Euronext ,Head Of Research ,European Commission ,Institute Gustave Roussy ,American Society Of Clinical Oncology Annual Meeting ,European Thyroid Association Guidelines For The Treatment ,Head Of Drug Development Department ,Ono Pharmaceutical Co ,European Union ,Takeda Pharmaceutical Company Limited ,Bristol Myers Squibb ,American Cancer Society ,American Society ,Clinical Oncology Annual Meeting ,Santiago Ponce Aix ,Drug Development Department ,Executive Vice President ,Plus Atezolizumab ,With Advanced Non Small Cell Lung Cancer ,Previously Treated With ,Immune Checkpoint Inhibitor ,Results From Cohorts ,Cancer Non Small Cell Metastatic ,Combination With Atezolizumab ,Urothelial Carcinoma ,Neck Cancer ,United Arabic Emirates ,Product Characteristics ,Rare Disease ,With Specialty Care ,Consumer Healthcare ,Sponsored Leveli American Depositary Receipt ,Forward Looking Statements ,French Autorit ,Des March ,Registration Document ,Health Organization ,Cancer Journal For ,Adv Med ,Thyroid Association Guidelines ,Advanced Radioiodine Refractory Thyroid ,Eur Thyroid ,Subjects With Locally Advanced ,Metastatic Solid Tumors ,Nivolumab Combined With Cabozantinib Compared ,Previously Untreated Advanced ,Metastatic Renal Cell Carcinoma ,Cabozantinib Compared With Placebo ,Targeted Therapy ,Investor Relations ,Relations Manager ,Franchise Communicationsoncology ,Lipsen ,Disco ,022 ,Cabometyx ,Data ,Show ,Ncouraging ,Results ,Monotherapy ,Combination ,Cross ,Different ,Humor ,Types ,Ncluding ,Metastatic ,Mall ,Fell ,Young ,Dancer ,